Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

G ALK TKI

For instance Unknown

Crizotinib

Ceritinib

Lorlatinib

Brigatinib

Alectinib

Ensartinib

PROFILE 1014

ASCEND 5

ASCEND 4

PHASE 2 trial

ASCEND-9

PHASE 2 trial

PHASE 1/2 trial

ALEX trial

ALTA-1L, PFS Not reached,, probably not lower?

ALEX trial

ALTA 90

180

ALUR

MGH Cohort

PHASE 2 trial

MGH Cohort

PHASE 2 trial

For instance, does PFS1 really matter?

Solomon – NEJM 2014 * Soria – Lancet 2016 * Camidge – ASCO 2018 * Camidge – NEJM 2018 * Lin, JTO 2018 * Novello – An Oncol 2018 * Hida, Cancer Sci 2018 *

Crino – JCO 2017 * Kim – JCO 2017 * Camidge – JCO 2018 * Shaw – Lancet Oncol 2016 * Gadgeel –JCO 2016 * Camidge – JCO 2018 * Felip – ESMO 2018

4-y OS

57%

ASCEND3 (ceritinib), mOS 51.3 mo.